Certolizumab、阿巴西普与英夫利西单抗生物类似药治疗类风湿关节炎的真实世界比较效果:丹麦DANBIO登记模拟随机试验
基于丹麦DANBIO登记,模拟随机试验比较了 certolizumab pegol(CZP)、阿巴西普(ABA)和英夫利西单抗生物类似药(CT-P13)在类风湿关节炎(RA)患者中的效果。6个月和12个月DAS28缓解率及1年治疗保留率在药物间无显著统计学差异,置信区间较宽。
要点
- 丹麦全国指南更替可模拟随机化,用于头对头比较三种生物制剂。
- 6个月DAS28缓解率:CZP 35%、ABA 33%、CT-P13 42%,差异无统计学意义。
- 12个月缓解率及1年治疗保留率在各药间亦无显著差异,置信区间宽。
核心结论
- 模拟随机化方法可行,CZP、ABA与CT-P13在估计效果上存在数值差异但未达统计学显著。
研究设计与样本
- 观察性队列研究,模拟随机试验,采用意向性治疗分析。
- 通过链接全国登记获取既往合并症信息,采用多变量logistic回归和Cox回归调整混杂因素。
主要发现
- 6个月DAS28缓解率分别为CZP 35%、ABA 33%、CT-P13 42%,12个月分别为35%、31%、35%。
- 与CZP相比,ABA的6个月和12个月缓解调整OR分别为0.96(95%CI 0.63-1.47)和0.74(95%CI 0.47-1.15)。
- 与CZP相比,CT-P13的6个月和12个月缓解调整OR分别为1.38(95%CI 0.91-2.09)和0.96(95%CI 0.62-1.49)。
- 与CZP相比,ABA在0-90天和91-365天撤药的调整HR分别为0.70(95%CI 0.39-1.27)和1.16(95%CI 0.84-1.60)。
- 与CZP相比,CT-P13在0-90天和91-365天撤药的调整HR分别为0.58(95%CI 0.33-1.10)和0.83(95%CI 0.59-1.17)。
关键数值与推荐
- 指南依从性:CZP 70%、ABA 65%、CT-P13 59%。
临床怎么用
- 在甲氨蝶呤联合治疗下,三种生物制剂均可作为生物制剂初治RA患者的选择,疗效差异不显著。
局限性
- 置信区间较宽,统计效能有限,不能排除有临床意义的差异。
- 观察性设计可能残余混杂,尽管采用了模拟随机化和多变量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nationwide Danish guidelines regarding rheumatoid arthritis (RA) patients initiating biologic treatment (i.e., biologic disease-modifying antirheumatic drugs [DMARDs]) are issued on an approximately annual basis. For biologics-naive patients treated with concomitant methotrexate, mandatory medications included certolizumab pegol (CZP; year 2013-2014, recommended compliance 80%), abatacept (ABA; 2014-2015, 80%), and biosimilar infliximab (CT-P13; 2015-2016, 50%). We hypothesized that these guidelines could be perceived as a surrogate randomization tool in which calendar period rather than patient-specific factors defined the choice of the biologic DMARD. We undertook this study to assess compliance with guidelines (supporting the assumption of surrogate randomization) and to compare the effectiveness of CZP, ABA, and CT-P13 in patients treated according to guidelines. METHODS: This was an observational cohort study emulating a randomized trial (using intent-to-treat analyses). RA patients compliant with the treatment guidelines were identified in DANBIO, and information on prior comorbidities was obtained by linking to national registries. Outcome measures included remission rates according to the Disease Activity Score in 28 joints (DAS28) (at 6 and 12 months) and treatment retention at 1 year, compared across treatment regimens. Comorbidity/confounder-adjusted multivariable logistic and Cox regression analyses were used. RESULTS: Seven hundred seventy-six patients were included in the study (336 receiving CZP, 215 receiving ABA, 225 receiving CT-P13). Compliance with treatment guidelines was high: 70%, 65%, and 59%, respectively. Six-month DAS28 remission rates were 35%, 33%, and 42%, and 12-month rates were 35%, 31%, and 35%, respectively. Compared to CZP, adjusted odds ratios for 6- and 12-month DAS28 remission rates were 0.96 (95% confidence interval [95% CI] 0.63-1.47) and 0.74 (95% CI 0.47-1.15) for ABA and 1.38 (95% CI 0.91-2.09) and 0.96 (95% CI 0.62-1.49) for CT-P13, respectively. Adjusted hazard ratios for withdrawal (during days 0-90 and days 91-365) were 0.70 (95% CI 0.39-1.27) and 1.16 (95% CI 0.84-1.60) for ABA and 0.58 (95% CI 0.33-1.10) and 0.83 (95% CI 0.59-1.17) for CT-P13, respectively, compared to CZP. CONCLUSION: The surrogate randomization procedure enabled head-to-head comparisons of CZP, ABA, and CT-P13. Although some differences in estimated effectiveness were observed across drugs, confidence intervals were wide and statistical significance was not reached.
引用
- Grøn KL, Glintborg B, Nørgaard M, et al. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial. Arthritis Rheumatol. 2019. PMID: 31268624. doi:10.1002/art.41031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。